- Home
- MRM vs CMND Comparison
MRM vs CMND Comparison
Compare MRM & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- CMND
- Stock Information
- Founded
- MRM 2000
- CMND 2017
- Country
- MRM Japan
- CMND Canada
- Employees
- MRM N/A
- CMND N/A
- Industry
- MRM Other Consumer Services
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- CMND Health Care
- Exchange
- MRM Nasdaq
- CMND Nasdaq
- Market Cap
- MRM 5.9M
- CMND 4.8M
- IPO Year
- MRM 2020
- CMND N/A
- Fundamental
- Price
- MRM $1.36
- CMND $0.85
- Analyst Decision
- MRM
- CMND
- Analyst Count
- MRM 0
- CMND 0
- Target Price
- MRM N/A
- CMND N/A
- AVG Volume (30 Days)
- MRM 44.6K
- CMND 122.4K
- Earning Date
- MRM 05-20-2025
- CMND 06-12-2025
- Dividend Yield
- MRM N/A
- CMND N/A
- EPS Growth
- MRM 27.65
- CMND N/A
- EPS
- MRM 0.18
- CMND N/A
- Revenue
- MRM $52,786,758.00
- CMND N/A
- Revenue This Year
- MRM N/A
- CMND N/A
- Revenue Next Year
- MRM N/A
- CMND N/A
- P/E Ratio
- MRM $8.41
- CMND N/A
- Revenue Growth
- MRM 21.55
- CMND N/A
- 52 Week Low
- MRM $0.34
- CMND $0.80
- 52 Week High
- MRM $8.39
- CMND $2.30
- Technical
- Relative Strength Index (RSI)
- MRM 49.70
- CMND 41.60
- Support Level
- MRM $1.32
- CMND $0.83
- Resistance Level
- MRM $1.50
- CMND $0.93
- Average True Range (ATR)
- MRM 0.09
- CMND 0.06
- MACD
- MRM -0.05
- CMND 0.00
- Stochastic Oscillator
- MRM 18.92
- CMND 32.64
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.